Key Highlights

  • LifeMD (NASDAQ:LFMD) was trading up 36.56% at USD 2.26 on Friday, November 13, 2026, in market data, which implies a prior close near USD 1.66 (calculated), after results released on November 12.
  • Third quarter Revenue was USD 44.6 million, down from USD 47.7 million, with a net loss of USD 5.2 million, or USD 0.11 per share, against a loss of USD 0.12 per share a year earlier.
  • Adjusted EBITDA was a loss of about USD 0.41 million, against a profit of USD 2.79 million a year earlier but an improvement of about USD 3.1 million from the second quarter loss of USD 3.5 million.
  • Full-year 2026 revenue guidance was lowered to USD 188 million to USD 191 million from USD 205.5 million to USD 212.5 million, and adjusted EBITDA guidance to a loss of USD 12.6 million to USD 10.6 million.

Smaller Loss Meets a Lower Outlook

LifeMD (NASDAQ:LFMD) was trading up 36.56% at USD 2.26 on Friday, November 13, 2026, after it reported third quarter results on November 12. Revenue was USD 44.6 million, down about 6.5% from USD 47.7 million (calculated), and published pre-report estimates of about USD 48.8 million point to a revenue shortfall. The net loss was USD 5.2 million, or USD 0.11 a share, narrower than the loss of USD 0.14 a share in those estimates. Gross Margin was about 82% versus about 85%, which the company attributed mainly to reporting branded medications dispensed by its pharmacy on a gross revenue basis.

Costs, Cash and the Fourth-Quarter Setup

Selling and Marketing spending fell 34% from the prior quarter to USD 18.5 million, which helped adjusted EBITDA come within about USD 0.41 million of breakeven. Fourth quarter guidance is revenue of USD 46 million to USD 49 million and adjusted EBITDA of a loss of USD 4 million to USD 2 million. Cash was USD 21.9 million with no Debt at quarter end, and after quarter end the company closed a USD 12.5 million senior secured term Loan with Avenue Capital that replaced its revolving Credit facility. Active subscribers were about 350,000, up 13% from a year earlier, and pharmacy shipment Volume rose 58.3%. General and administrative expense was USD 14.7 million, up 6% from a year earlier, and deeper marketing cuts lift margins but can slow subscriber growth.

GLP-1 Access, an AT&T Link and Execution Risk

LifeMD said it has arrangements with Novo Nordisk and Eli Lilly that let its pharmacy dispense self-pay branded GLP-1 medications nationwide, and an exclusive relationship with AT&T that opens its services to that carrier's wireless and fiber customers and employees. It plans to market an enterprise healthcare offering in the fourth quarter. As of a November 2 preview, shares had fallen about 29% since the prior report, per published coverage, so the rally follows a deep drop. Risks include another outlook cut, revenue decline, margin pressure and new debt.

Where Things Stand

Results released on November 12, 2026 are the likeliest reason for the 36.56% rise, though no one item was confirmed as the cause. LifeMD (NASDAQ:LFMD) cut its full-year outlook and posted lower revenue, yet the loss was smaller than expected, adjusted EBITDA nearly reached breakeven and a term loan and GLP-1 and AT&T arrangements were announced. Next markers are fourth quarter revenue against the USD 46 million to USD 49 million guide and the enterprise launch.